TriSalus Life Sciences is asking the market to treat a first-half commercial rebuild as an investment, not a demand problem. The Westminster, Colorado oncology-device company more than doubled its sales footprint between February and April, disrupted a large share of existing territories in the opening quarter, and then printed a sequential rebound in the period ended June 30 that management used to keep full-year revenue guidance intact after the earlier cut. The debate is whether that rebound is the first evidence that a rebuilt interventional-radiology call point can convert a high-margin catheter franchise into second-half acceleration, or whether the company merely spent equity proceeds to stand still against last year's run-rate.
The economic shape of the quarter is more revealing than the year-over-year comparison. Revenue of $11.4 million was only a sliver above the year-ago print, yet it recovered sharply from the $8.9 million first-quarter stall that management blamed on the rebuild rather than weaker procedure demand. Gross margin expanded to 86.8 percent on lower unit cost, which is the signature of a disposable catheter business that already makes money at the product level. Sales and marketing of $11.4 million essentially matched the entire revenue line, so the operating loss widened even as research and administrative spending receded. Cash ended at $46.3 million after a first-quarter equity raise of $46.0 million in gross proceeds, which is the balance-sheet fact that makes the rebuild affordable in the near term and still leaves the franchise dependent on execution rather than another immediate financing.
The second-half math is the entire thesis. Hitting the maintained $54 million to $57 million guide after a flat first half requires a clear step-up in commercial productivity once onboarding costs fade, plus some help from reimbursement and product timing that the first half did not deliver. A Centers for Medicare and Medicaid Services notice of a G-code aimed at office-based labs could open a setting that hospital-only codes do not cover, while clearance of the delayed TriNav Advance microcatheter remains a second-half product event rather than a booked contributor. The question the next two prints have to answer is simple: does the doubled force start selling enough incremental TriNav units to cover its own cost, or does the company discover that high gross margin cannot outrun a sales engine that is still learning the territory?